September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
6 citations
,
April 2016 in “Australasian journal of dermatology” Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
5 citations
,
November 2024 in “Journal of Clinical Immunology” Dupilumab effectively controls symptoms in infants with Netherton syndrome.
September 2024 in “Journal of the American Academy of Dermatology” Early intervention is important for limited systemic sclerosis patients due to higher pain and ulceration risks.
January 2014 in “IOSR journal of pharmacy” Adalimumab can cause complete hair loss in rare cases.
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
1 citations
,
October 2013 in “The American Journal of Gastroenterology” Infliximab can trigger lupus-like symptoms in Crohn's disease patients.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
April 2023 in “Journal of Investigative Dermatology” The research found that a protein called caveolin-1 is reduced in psoriasis, but reintroducing it can help alleviate some psoriasis symptoms.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors may help treat other skin conditions, but more research is needed.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
25 citations
,
May 2019 in “Biologics” Dupilumab can cause rare side effects like a rash on the face and neck.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
July 2024 in “Journal of Investigative Dermatology”